368 related articles for article (PubMed ID: 25761234)
1. Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia.
Pac L; Horwitz MM; Namutebi AM; Auerbach BJ; Semeere A; Namulema T; Schwarz M; Bbosa R; Muruta A; Meya DB; Manabe YC
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):e69-76. PubMed ID: 25761234
[TBL] [Abstract][Full Text] [Related]
2. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.
Liechty CA; Solberg P; Were W; Ekwaru JP; Ransom RL; Weidle PJ; Downing R; Coutinho A; Mermin J
Trop Med Int Health; 2007 Aug; 12(8):929-35. PubMed ID: 17697087
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and outcomes of cryptococcal antigenemia in HIV-seropositive patients hospitalized for suspected tuberculosis in Uganda.
Andama AO; den Boon S; Meya D; Cattamanchi A; Worodria W; Davis JL; Walter ND; Yoo SD; Kalema N; Haller B; Huang L;
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):189-94. PubMed ID: 23542636
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
[TBL] [Abstract][Full Text] [Related]
5. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
Meya DB; Kiragga AN; Nalintya E; Morawski BM; Rajasingham R; Park BJ; Mubiru A; Kaplan JE; Manabe YC; Boulware DR
J Acquir Immune Defic Syndr; 2019 Feb; 80(2):182-189. PubMed ID: 30399034
[TBL] [Abstract][Full Text] [Related]
6. Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm
Wykowski J; Galagan SR; Govere S; Wallis CL; Moosa MY; Celum C; Drain PK
BMC Infect Dis; 2020 Jan; 20(1):61. PubMed ID: 31959112
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
Lakoh S; Rickman H; Sesay M; Kenneh S; Burke R; Baldeh M; Jiba DF; Tejan YS; Boyle S; Koroma C; Deen GF; Beynon F
BMC Infect Dis; 2020 Feb; 20(1):141. PubMed ID: 32059703
[TBL] [Abstract][Full Text] [Related]
8. No association of cryptococcal antigenemia with poor outcomes among antiretroviral therapy-experienced HIV-infected patients in Addis Ababa, Ethiopia.
Smitson CC; Tenna A; Tsegaye M; Alemu AS; Fekade D; Aseffa A; Blumberg HM; Kempker RR
PLoS One; 2014; 9(1):e85698. PubMed ID: 24465651
[TBL] [Abstract][Full Text] [Related]
9. Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia.
Kapoor SW; Magambo KA; Kalluvya SE; Fitzgerald DW; Peck RN; Downs JA
AIDS; 2015 Nov; 29(18):2473-8. PubMed ID: 26372487
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda.
Nalintya E; Meya DB; Lofgren S; Huppler Hullsiek K; Boulware DR; Rajasingham R
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):231-238. PubMed ID: 29509588
[TBL] [Abstract][Full Text] [Related]
11. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa.
Jarvis JN; Lawn SD; Vogt M; Bangani N; Wood R; Harrison TS
Clin Infect Dis; 2009 Apr; 48(7):856-62. PubMed ID: 19222372
[TBL] [Abstract][Full Text] [Related]
12. Cryptococcal antigenemia and associated risk factors among ART-naïve and ART-experienced HIV-infected peoples at selected health institutions of Mekelle, Northern Ethiopia.
Hailu K; Niguse S; Hagos K; Abdulkader M
Microbiologyopen; 2019 Jun; 8(6):e00746. PubMed ID: 30277315
[TBL] [Abstract][Full Text] [Related]
13. Opportunistic diseases diminish the clinical benefit of immediate antiretroviral therapy in HIV-tuberculosis co-infected adults with low CD4+ cell counts.
Worodria W; Ssempijja V; Hanrahan C; Ssegonja R; Muhofwa A; Mazapkwe D; Mayanja-Kizza H; Reynolds SJ; Colebunders R; Manabe YC
AIDS; 2018 Sep; 32(15):2141-2149. PubMed ID: 30005014
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cryptococcal antigenemia between antiretroviral naïve and antiretroviral experienced HIV positive patients at two hospitals in Ethiopia.
Beyene T; Woldeamanuel Y; Asrat D; Ayana G; Boulware DR
PLoS One; 2013; 8(10):e75585. PubMed ID: 24124498
[TBL] [Abstract][Full Text] [Related]
15. Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil.
Vidal JE; Toniolo C; Paulino A; Colombo A; Dos Anjos Martins M; da Silva Meira C; Pereira-Chioccola VL; Figueiredo-Mello C; Barros T; Duarte J; Fonseca F; Alves Cunha M; Mendes C; Ribero T; Dos Santos Lazera M; Rajasingham R; Boulware DR
Trop Med Int Health; 2016 Dec; 21(12):1539-1544. PubMed ID: 27699970
[TBL] [Abstract][Full Text] [Related]
16. Point-of-care lateral flow assays for tuberculosis and cryptococcal antigenuria predict death in HIV infected adults in Uganda.
Manabe YC; Nonyane BA; Nakiyingi L; Mbabazi O; Lubega G; Shah M; Moulton LH; Joloba M; Ellner J; Dorman SE
PLoS One; 2014; 9(7):e101459. PubMed ID: 25000489
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the initial 12 months of a routine cryptococcal antigen screening program in reduction of HIV-associated cryptococcal meningitis in Uganda.
Enock K; Julius K; Griffith BC; Abila DB; Rutakingirwa MK; Kasibante J; Kandole KT; Kwizera R; Semeere A; Meya DB
BMC Health Serv Res; 2022 Mar; 22(1):301. PubMed ID: 35246128
[TBL] [Abstract][Full Text] [Related]
18. Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study.
Longley N; Jarvis JN; Meintjes G; Boulle A; Cross A; Kelly N; Govender NP; Bekker LG; Wood R; Harrison TS
Clin Infect Dis; 2016 Mar; 62(5):581-587. PubMed ID: 26565007
[TBL] [Abstract][Full Text] [Related]
19. Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa.
Larson BA; Rockers PC; Bonawitz R; Sriruttan C; Glencross DK; Cassim N; Coetzee LM; Greene GS; Chiller TM; Vallabhaneni S; Long L; van Rensburg C; Govender NP
PLoS One; 2016; 11(7):e0158986. PubMed ID: 27390864
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Cryptococcal Antigen Screening of HIV-Infected Patients in Iran.
Bandalizadeh Z; Shokohi T; Moosazadeh M; Keikha N; Seyedpor H; Rabie Rudsari M; Babamahmoudi F; Ghasemian R; Mardani M; Javanian M; Soleimanpour S; Sefidgar AA; Shokri M; Gouya MM; Seyedmousavi S
Curr Microbiol; 2020 Aug; 77(8):1667-1672. PubMed ID: 32296917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
